Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment.

被引：0

作者：

Pressiani, T.

Rimassa, L.

Boni, C.

Labianca, R.

Fagiuoli, S.

Ardizzoni, A.

Foa, P.

Cortesi, E.

Porta, C.

Artioli, F.

Latini, L.

Carnaghi, C.

Lutman, R. F.

Torzilli, G.

Tommasini, M.

Ceriani, R.

Covini, G.

Giordano, L.

Locopo, N.

Santoro, A.

机构：

[1] Humanitas Canc Ctr, Rozzano, Italy

[2] Arcispedale S Maria Nuova, Div Oncolgy, Reggio Emilia, Italy

[3] Osped Riuniti Bergamo, Bergamo, Italy

[4] Azienda Osped Univ, Unita Oncol Med, Parma, Italy

[5] Azienda Osped San Paolo, Milan, Italy

[6] Policlin Umberto 1, Div Med Oncol, Rome, Italy

[7] IRCCS Policlin San Matteo, Pavia, Italy

[8] Ramazzini Hosp, Div Med Oncol, Carpi, Italy

[9] Osped Gen Prov, Macerata, Italy

[10] Humanitas Canc Ctr, Dept Gen Surg, Rozzano, Italy

[11] Univ Milan, Sch Med, Rozzano, Italy

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4115

引用

页数：1